Multiple Sclerosis Clinical Trials in Massachusetts

37 recruiting studies across 1 city

Browse by City

All Trials in Massachusetts

Phase

Trial	Phase	Sponsor	Dist.
Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study	Phase 2	Darcy Krueger	<1 mi
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO	Phase 1	National Cancer Institute (NCI)	<1 mi
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses	Phase 2	Reunion Neuroscience Inc	<1 mi
TSC Biosample Repository and Natural History Database	—	National Tuberous Sclerosis Association	<1 mi
PET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric Diseases	Phase 1/2	Brigham and Women's Hospital	<1 mi
A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Milk	—	TG Therapeutics, Inc.	<1 mi
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis	Phase 2	Novartis Pharmaceuticals	<1 mi
AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy	Phase 1/2	UniQure Biopharma B.V.	<1 mi
Molecular Imaging of NET Using [C-11]MRB-PET in MS	Phase 1/2	Brigham and Women's Hospital	<1 mi
Efgartigimod for the Treatment of Acute Optic Neuritis	Phase 2	Anastasia Vishnevetsky, MD, MPH	<1 mi
Controlling Amyotrophic Lateral Sclerosis Motor Neuron Excitability Study	N/A	PathMaker Neurosystems Inc.	<1 mi
Investigating the Utility of Demyelination Tracer [18F]3F4AP in Controls and Multiple Sclerosis Subjects	Phase 1	Massachusetts General Hospital	<1 mi
Assessment of Synaptic Density in MS	Early 1	Brigham and Women's Hospital	<1 mi
A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years	Phase 2	ModernaTX, Inc.	<1 mi
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.	Phase 3	Novartis Pharmaceuticals	<1 mi
Glucose Consumption in MS Using [F-18]FDG-PET	Phase 4	Brigham and Women's Hospital	<1 mi
Study of COYA 302 for the Treatment of ALS	Phase 2	Coya Therapeutics	<1 mi
Nasal Foralumab in Patients With Non-Active Secondary Progressive Multiple Sclerosis	Phase 2	Tiziana Life Sciences LTD	<1 mi
Care in Multiple Sclerosis (MS)	—	NYU Langone Health	<1 mi
AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis	Phase 1	Amylyx Pharmaceuticals Inc.	<1 mi
Genes and Environment in Multiple Sclerosis	—	Columbia University	<1 mi
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)	—	TG Therapeutics, Inc.	<1 mi
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab	Phase 3	TG Therapeutics, Inc.	<1 mi
Dalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis	Phase 3	MGH Institute of Health Professions	<1 mi
Vascular Mechanisms, Functional Outcomes, & Exercise Among Persons With Multiple Sclerosis With Hypertension	N/A	University of Massachusetts, Boston	<1 mi
Prevalence and Impact of Obstructive Sleep Apnea in Multiple Sclerosis	—	Beth Israel Deaconess Medical Center	<1 mi
Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis	Phase 4	National Institute of Allergy and Infectious Diseases (NIAID)	<1 mi
A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis	Phase 3	Zenas BioPharma (USA), LLC	<1 mi
A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease	—	TScan Therapeutics, Inc.	9 mi
Confirmatory Trial for Alleviating Fatigue in Multiple Sclerosis	N/A	Accelerated Cure Project for Multiple Sclerosis	9 mi
IConquerMS™ - a Patient-Powered Research Network for Multiple Sclerosis	—	Accelerated Cure Project for Multiple Sclerosis	9 mi
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis	Phase 3	Novartis Pharmaceuticals	13 mi
A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity	Phase 2	Celgene	23 mi
A Single-Center Study to Characterize the Safety and Efficacy of Ublituximab in Older Adults With Relapsing Forms of Multiple Sclerosis (RMS)	—	Neurology Center of New England P.C.	23 mi
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)	Phase 3	National Institute of Allergy and Infectious Diseases (NIAID)	39 mi
A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)	Phase 2	Hoffmann-La Roche	39 mi
A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis	Phase 1	Hoffmann-La Roche	39 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.